Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
A new study concludes it costs $757 million to develop a new cancer drug, but is that the only reason why drugmakers charge sky-high drug prices or are other reasons to blame too?
Note: Audio transcripts are not currently available for podcast episodes. Episode description provided above contains key topics and insights.
Dec 31, 2021 (00:00:00)
Note: Audio transcripts are not currently available for podcast episodes. Episode description provided above contains key topics and insights.
Dec 22, 2021 (00:25:33)
Nick, Emily, Jason, and Dylan get together to talk through the companies they've learned the most from, the stocks they've sold recently (and why!) and also where you can catch all of them with The Motley Fool's new audio offering in 2022.
Stocks: MELI, SHOP, GME, BBY
Check out more of our content here:
Reach us by Email @ [email protected]
Note: Audio transcripts are not currently available for podcast episodes. Episode description provided above contains key topics and insights.
Dec 21, 2021 (00:25:41)
In this last iteration of Industry Focus Consumer Goods (don’t worry - we’re just moving to Motley Fool Money!), Emily Flippen and Asit Sharma revisit their 2021 consumer goods basket as well as reflect on lessons learned from investing in the industry at large.
Stocks: Grocery Outlet (GO), Peloton (PTON), Beyond Meat (BYND), Dollar General (DG), and Sleep Number (SNBR)
Check out more of our content here:
Reach us by Email @ [email protected]
Note: Audio transcripts are not currently available for podcast episodes. Episode description provided above contains key topics and insights.
Dec 20, 2021 (00:20:28)
On this week’s episode of Industry Focus: Financials host Jason Moser sits down with Motley Fool contributor Dan Caplinger. Tune in as they discuss why regulators are taking a closer look at the buy now pay later space. Then they wrap up the show with a listener question on where to put non-stock portfolio cash.
Check out more of our content here:
Reach us by Email @ [email protected]
Note: Audio transcripts are not currently available for podcast episodes. Episode description provided above contains key topics and insights.
Dec 17, 2021 (00:26:39)
We revisit all the new companies we talked about in 2021, look at the landscape of the IPO market in general, and zoom in on some of the most interesting debuts from the year.
Stocks: OLO, KNBE, GLBE
Listener survey: https://www.foolinsights.com/se/04BD76CC18830996
Check out more of our content here:
Reach us by Email @ [email protected]
Note: Audio transcripts are not currently available for podcast episodes. Episode description provided above contains key topics and insights.
Dec 16, 2021 (00:26:11)
Jason Hall and Matt DiLallo join the show to break down the defining energy themes of 2021 and share their predictions for 2022
Stocks Mentioned: PSX, DAR, VLO, KMI, WMB, ET, GTLS, BP, TTE, XOM, CVX, BKR, DVN, PXD, COP, EOG, TPIC, BAM
Check out more of our content here:
Reach us by Email @ [email protected]
Note: Audio transcripts are not currently available for podcast episodes. Episode description provided above contains key topics and insights.
Dec 15, 2021 (00:26:03)
We get back to Wednesday's healthcare roots with a rundown on BICO Group, a Sweden-based business that enables researchers and scientists to model, build, test, analyze and observe 3-D printed cells, tissues and organs.
This company helps researchers reduce the time and cost of identifying potentially efficacious drugs and can help provide initial results on whether drug compounds are safe and effective before having to test them on animals or humans.
We talk through the huge implications it could have for research in life sciences and personalized medicine and try to clear up some of the jargon around the company.
Stocks: (OM:BICO)
Check out more of our content here:
Reach us by Email @ [email protected]
Note: Audio transcripts are not currently available for podcast episodes. Episode description provided above contains key topics and insights.
Dec 14, 2021 (00:26:01)
Olaplex is a nearly $17 billion dollar hair care business that has made its name by combining science with influence. But does this recent IPO have what it takes to be the next best consumer goods business? Join Motley Fool analysts Sanmeet Deo and Emily Flippen as they discuss the tailwinds and challenges of investing in haircare.
Stocks: Olaplex Holdings (NASDAQ: OLPX)
Check out more of our content here:
Reach us by Email @ [email protected]
Note: Audio transcripts are not currently available for podcast episodes. Episode description provided above contains key topics and insights.
Dec 13, 2021 (00:18:54)
In this week's edition of Industry Focus: Financials, we take a look back at the stock market predictions Fool.com contributor Matt Frankel made in December of last year and see how he did. And then, Matt and host Jason Moser discuss his 2022 predictions and why he thinks they have a good chance of actually happening.
Check out more of our content here:
Reach us by Email @ [email protected]
Note: Audio transcripts are not currently available for podcast episodes. Episode description provided above contains key topics and insights.